ClinicalTrials.gg
RecruitingNCT06173011Updated Jan 23, 2024

A Study Comparing Pharmacokinetic and Safety of QL2107 and Keytruda® (Marketed in China and the United States) in Healthy Adults

A Phase 1 interventional study of QL2107 and Keytruda®(china) in Tumor, sponsored by Qilu Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-23.

Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2024, 2 years 4 months ago, but the record still lists the study as recruiting.
  • Started Dec 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
168
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Male
01

Study summary

The goal of this clinical trial is to compare the pharmacokinetic and safety similarity of QL2107 with Keytruda® marketed in China and the United States in healthy male volunteers.

Participants will receive a single injection of QL2107/ Keytruda® (China)/Keytruda® (US).Researchers will compare pharmacokinetic, safety, and immunogenic similarities between the three groups.

Read the detailed description

This is a phase I,single center, randomized, double-blind and parallel group clinical trial .

The primary objective is to assess the pharmacokinetic similarity of single injections of QL2107 or Keytruda® (China/US) in healthy volunteers.

The secondary objective are to assess the clinical safety and immunogenicity similarity of single injections of QL2107 or Keytruda® (China/US) in healthy volunteers.

Subjects would receive a single 100mg(4ml) of QL2107or Keytruda® (China/US)injection.

02

Conditions studied

  • Tumor

Browse trials for

03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 168 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Qilu Pharmaceutical Co., Ltd. is the lead sponsor of 200 studies on the registry; 122 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  1. Sign the form and fully understand the test content, process and possible adverse reactions, and be able to complete the study according to the test plan requirements;
  2. Age 18 \~ 50 (inclusive) years , male;
  3. 50.0 kg≤ body weight ≤90.0 kg and 18.0 kg/m2≤ (BMI) ≤28.0 kg/m2;
  4. Agree to use effective throughout the study period (including but not limited to: physical contraception, surgery, abstinence, etc.) until at least 6 months after the study dosing;
  5. No history of disease or abnormal past medical history is not , and the study doctor's judgment has no impact on the trial.

Exclusion criteria

Exclusion Criteria:

  1. Clinical laboratory examination, infectious disease screening, chest orthogram examination, abdominal color ultrasound examination, 12-lead , heart color ultrasound, physical examination, vital signs (systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mmHg) the abnormalities in each examination have clinical significance or are determined to have an impact on the trial (subject to the judgment of the clinical study physician);

(2) Have been or are currently suffering from any clinically serious disease of the circulatory system, endocrine system, nervous system, digestive system, respiratory system, urogenital system, hematology, immunology, psychiatric and metabolic abnormalities, or any other disease that can interfere with the test results;

  1. Presence of any active disease or history of autoimmune disease (including but not limited to: rheumatoid arthritis, ankylosing spondylitis, autoimmune hemolytic anemia, interstitial pneumonia, uveitis, inflammatory bowel disease, autoimmune hepatitis, autoimmune pituitaritis, glomerulonephritis, hyperthyroidism or hypothyroidism, etc.)
  1. Known history of tuberculosis or suspected clinical manifestations of tuberculosis (including but not limited to tuberculosis, lymphatic tuberculosis, tuberculous pleurisy, etc.);
  1. Patients with a history of acute infection within 2 weeks before screening;
  1. There have been herpes zoster virus infections within 3 months before screening;
  1. Viral hepatitis (including and C), AIDS antibody, treponema pallidum antibody screening positive;
  1. Allergies (multiple drug and food allergies), who were determined by the researcher to be unable to participate in this study;
  1. Patients who had surgery within 4 weeks prior to screening or planned to have surgery during the study period;
  1. Those who have used any biological product or received live viral vaccine (tetanus toxoid vaccine within 1 year before infusion), used any monoclonal antibody within 6 months or 5 biological half-lives of drug metabolism, or used /PD-L1 drugs in the past;
  1. Those who have used any drug or health product (including Chinese herbal medicine) within 14 days prior to the infusion of the experimental drug;
  1. Participants who participated in any clinical trial and used any clinical trial drug within 3 months prior to screening;
  1. Study patients who donated blood or lost a large amount of blood (> 400 mL) or received blood transfusions or used blood products within 3 months prior to administration;
  1. Smokers or smokers who smoked more than 5 cigarettes per day in the 3 months prior to screening or who could not stop using any tobacco products during the trial;
  1. Positive drug screening or/and alcohol breath test screening prior to study administration;
  1. A history of drug and/or alcohol abuse (14 units of alcohol consumed per week "1 unit = 285 mL for beer, 25 mL for spirits, or 100 mL for wine");
  1. Subjects who have other factors deemed unsuitable for the study by the investigator;
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
168 participants (estimated)

Study arms

  • Experimental
    QL2107

    QL2107, intravenous infusion 35 min (±5min, minimum infusion 30min), D1 (Day 1, single dose)

    Drug: QL2107

  • Active comparator
    Keytruda®(china)

    Keytruda® (china), intravenously infusion 35 min (±5min, at least 30min), D1 (Day 1, single dose);

    Drug: Keytruda®(china)

  • Active comparator
    Keytruda®(US)

    Keytruda® (US), intravenously infusion 35 min (±5min, at least 30min), D1 (Day 1, single dose);

    Drug: Keytruda®(US)

Interventions

  • DrugQL2107

    intravenous infusion 35 min (±5min, minimum infusion 30min), D1 (Day 1, single dose)

  • intravenous infusion 35 min (±5min, minimum infusion 30min), D1 (Day 1, single dose)

  • intravenous infusion 35 min (±5min, minimum infusion 30min), D1 (Day 1, single dose)

06

What researchers measure

Primary outcomes

  1. AUC0-∞

    To evaluate pharmacokinetic similarity between QL2107 and Keytruda® (china/US)after a single intravenous infusion in healthy volunteers

    Time frame: 113day

Secondary outcomes

  1. safety and immunogenicity

    Safety, as defined by the rate of treatment-related adverse events as assessed by NCI CTCAE v5.0.after a single intravenous infusion in healthy volunteers;Immunogenicity will be assessed by the incidence of ADA and Nab.

    Time frame: 113day

  2. Cmax

    To evaluate pharmacokinetic similarity between QL2107 and Keytruda®

    Time frame: 113day

  3. Tmax

    To evaluate pharmacokinetic similarity between QL2107 and Keytruda®

    Time frame: 113day

  4. AUC0-t

    To evaluate pharmacokinetic similarity between QL2107 and Keytruda®

    Time frame: 113day

  5. t1/2

    To evaluate pharmacokinetic similarity between QL2107 and Keytruda®

    Time frame: 113day

  6. CL

    To evaluate pharmacokinetic similarity between QL2107 and Keytruda®

    Time frame: 113day

  7. Vd

    To evaluate pharmacokinetic similarity between QL2107 and Keytruda®

    Time frame: 113day

  8. AUC_%Extrap

    To evaluate pharmacokinetic similarity between QL2107 and Keytruda®

    Time frame: 113day

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Jul 2024, 7 months after the start.

Of 677 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 62. This study's planned 7 months is below that.

Counting every sponsor, half of 904 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2023
First posted
Dec 15, 2023
StartActual
Dec 12, 2023
Primary completionEst.
Jul 2024
CompletionEst.
Jul 2024
Last update
Jan 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06173011
Responsible party
Sponsor
First posted
Dec 15, 2023
Start date
Dec 12, 2023
Primary completion
Jul 2024 (estimated)
Completion
Jul 2024 (estimated)
Last update
Jan 23, 2024

Study contacts

yanhua ding
Contact
dingyanhua2003@126.com
0431-88782168

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: QL2107

Start the discussion